Redhill Biopharma
RDHL
17 hedge funds and large institutions have $782K invested in Redhill Biopharma in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 3 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
87% more capital invested
Capital invested by funds: $419K → $782K (+$363K)
0% more ownership
Funds ownership: 0% → 0% (+0%)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
6% less funds holding
Funds holding: 18 → 17 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$756K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$664K |
| 3 |
GS
Gagnon Securities
New York
|
+$50.2K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$41.9K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$12.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAC
Cowen and Company
New York
|
-$346K |
| 2 |
National Bank of Canada
Montreal,
Quebec, Canada
|
-$1.26K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$523 |
| 4 |
Morgan Stanley
New York
|
-$209 |
| 5 |
JP Morgan Chase
New York
|
-$78 |
RDHL Hedge Fund Activity: Q3 2023 in Review
17 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Redhill Biopharma (RDHL) for Q3 2023, worth a combined $782K — up 87% from $419K a quarter earlier.
Fund positioning in RDHL was balanced in Q3 2023: 3 funds opened new positions, 3 closed out, 5 added to existing stakes and 2 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $756K. The largest seller was Cowen and Company, exiting entirely with an estimated $346K sold.
- 17 institutional investors held Redhill Biopharma (RDHL) as of Q3 2023, down from 18 in Q2 2023.
- Funds reported $782K of Redhill Biopharma stock for Q3 2023, up 87% quarter-over-quarter.
- 3 funds opened new Redhill Biopharma positions in Q3 2023 and 3 closed out, a net change of 0 holders.
- The largest Redhill Biopharma buyer in Q3 2023 was Armistice Capital, an estimated $756K added.
- The largest Redhill Biopharma seller in Q3 2023 was Cowen and Company, an estimated $346K sold.
Based on aggregated 13F filings for Q3 2023.